Nanjing Vazyme Biotech Co Ltd
Nanjing Vazyme Biotech Co., Ltd offers technology solutions for life science, biomedicine, and in vitro diagnostics. The company offers nucleic acid extraction reagents, including DNA extraction, RNA extraction, microbiome nucleic acid extraction, sample treatment, and high-throughput automated extraction; molecular biology reagents comprising PCR, cloning/mutagenesis, reverse transcription, real… Read more
Nanjing Vazyme Biotech Co Ltd (688105) - Total Assets
Latest total assets as of September 2025: CN¥5.01 Billion CNY
Based on the latest financial reports, Nanjing Vazyme Biotech Co Ltd (688105) holds total assets worth CN¥5.01 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Nanjing Vazyme Biotech Co Ltd - Total Assets Trend (2017–2024)
This chart illustrates how Nanjing Vazyme Biotech Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Nanjing Vazyme Biotech Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Nanjing Vazyme Biotech Co Ltd's total assets of CN¥5.01 Billion consist of 70.7% current assets and 29.3% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 8.6% |
| Accounts Receivable | CN¥503.13 Million | 10.0% |
| Inventory | CN¥362.18 Million | 7.2% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥95.19 Million | 1.9% |
| Goodwill | CN¥130.49 Million | 2.6% |
Asset Composition Trend (2017–2024)
This chart illustrates how Nanjing Vazyme Biotech Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Nanjing Vazyme Biotech Co Ltd's current assets represent 70.7% of total assets in 2024, a decrease from 76.6% in 2017.
- Cash Position: Cash and equivalents constituted 8.6% of total assets in 2024, down from 47.1% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 10.0% of total assets.
Nanjing Vazyme Biotech Co Ltd Competitors by Total Assets
Key competitors of Nanjing Vazyme Biotech Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx SE
OTCGREY:ARGNF
|
USA | $7.18 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Exicure Inc
NASDAQ:XCUR
|
USA | $15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Nanjing Vazyme Biotech Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Nanjing Vazyme Biotech Co Ltd generates 0.27x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Nanjing Vazyme Biotech Co Ltd is currently not profitable relative to its asset base.
Nanjing Vazyme Biotech Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.73 | 4.69 | 4.18 |
| Quick Ratio | 3.34 | 4.17 | 3.69 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥2.68 Billion | CN¥ 2.69 Billion | CN¥ 854.06 Million |
Nanjing Vazyme Biotech Co Ltd - Advanced Valuation Insights
This section examines the relationship between Nanjing Vazyme Biotech Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.05 |
| Latest Market Cap to Assets Ratio | 0.11 |
| Asset Growth Rate (YoY) | -12.1% |
| Total Assets | CN¥5.05 Billion |
| Market Capitalization | $534.52 Million USD |
Valuation Analysis
Below Book Valuation: The market values Nanjing Vazyme Biotech Co Ltd's assets below their book value (0.11 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Nanjing Vazyme Biotech Co Ltd's assets decreased by 12.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Nanjing Vazyme Biotech Co Ltd (2017–2024)
The table below shows the annual total assets of Nanjing Vazyme Biotech Co Ltd from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥5.05 Billion | -12.14% |
| 2023-12-31 | CN¥5.75 Billion | -4.31% |
| 2022-12-31 | CN¥6.01 Billion | +30.35% |
| 2021-12-31 | CN¥4.61 Billion | +185.87% |
| 2020-12-31 | CN¥1.61 Billion | +396.91% |
| 2019-12-31 | CN¥324.33 Million | +29.35% |
| 2018-12-31 | CN¥250.75 Million | +33.10% |
| 2017-12-31 | CN¥188.40 Million | -- |